Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Acetylleucine→

Acetylleucine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
99-15-0
Molecular formula
C8H15NO3
Molecular weight
173.21 g/mol
Drug class
N-acetylated amino-acid derivativevestibular symptom-modulating agent
Mechanism of action
The mechanism is not established. Proposed actions include modulation of membrane potential in vestibular neuronal networks and support of central vestibular compensation; these mechanisms remain hypotheses.
Indications / reported uses
  • Used in some countries for symptomatic treatment of vertigo and dizziness. Clinical efficacy evidence remains limited; a systematic review found no randomised controlled trials demonstrating efficacy through September 2018.

Sources: https://pubmed.ncbi.nlm.nih.gov/30613860/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC10808386/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Acetylleucine Environmental Risk Assessment (ERA) (the Acetylleucine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.